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Abstract
Introduction
Metabolic syndrome (MetS) is increasing among young 
people. We compared the use of homeostasis model assess-
ment of insulin resistance (HOMA-IR) with the use of 
fasting blood glucose to identify MetS in African American 
children.
Methods
We performed a cross-sectional analysis of data from a 
sample of 105 children (45 boys, 60 girls) aged 9 to 13 
years with body mass indexes at or above the 85th percen-
tile for age and sex. Waist circumference, blood pressure, 
and fasting levels of blood glucose, insulin, triglycerides, 
and high-density lipoprotein cholesterol were measured.
Results
We found that HOMA-IR is a stronger indicator of MetS 
in children than blood glucose. Using HOMA-IR as 1 of the 
5 components, we found a 38% prevalence of MetS in this 
sample of African American children and the proportion 
of false negatives decreased from 94% with blood glucose 
alone to 13% with HOMA-IR. The prevalence of MetS 
was higher in obese than overweight children and higher 
among girls than boys.
Conclusion
Using HOMA-IR was preferred to fasting blood glucose 
because insulin resistance was more significantly inter-
related with the other 4 MetS components. 
Introduction
Metabolic syndrome (MetS) is a cluster of the most dan-
gerous risk factors for type 2 diabetes mellitus and car-
diovascular disease (CVD). Clinical diagnosis of MetS in 
adults includes the presence of at least 3 of 5 conditions: 
elevated triglycerides, low high-density lipoprotein choles-
terol (HDL-C), high fasting blood glucose, high blood pres-
sure, and obesity (1). Many professional groups, including 
the World Health Organization, National Cholesterol 
Education Program Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults 
(Adult Treatment Panel III), International Diabetes 
Federation (IDF), the American Diabetes Association, and 
the American Heart Association have offered definitions 
of MetS for adults, but these definitions cannot be used 
directly for children. Because MetS incidence is increasing 
rapidly (2), it is vital to identify MetS during childhood 
to prevent the progression to CVD and type 2 diabetes in 
adulthood. Laboratory screening of children for MetS can 
be an impractical approach, so efforts have been made to 
develop simple screening criteria to identify children who 
need further testing. Previous studies have modified the 
criteria for adults when investigating MetS prevalence in 
children and adolescents (3-7). 
The recent IDF consensus definition for children has been 
built on these previously published definitions, using sex- 
and age-specific cut points (8). Even though metabolic dis-
eases may be influenced by race/ethnicity (9), the IDF did 
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not consider racial/ethnic endpoints. Cut points specific 
to sex, age, and race/ethnicity for body mass index (BMI) 
and waist circumference (10) have been used to determine 
the prevalence of MetS in a sample of children aged 13 to 
15 years, predominantly African American girls (11). The 
prevalence of MetS in younger African American girls and 
in African American boys has not been reported to our 
knowledge nor has there been a comparison by sex. Being 
overweight is associated with higher incidence of MetS 
in adolescents (3,12), but few data are available regard-
ing the prevalence of MetS specifically in overweight and 
obese African American children.
We aimed to 1) identify the prevalence of MetS in over-
weight and obese African American boys and girls aged 
9 to 13 years living in inner-city Oakland, California, 
2) determine whether the prevalence of MetS is higher 
in obese than in overweight African American children, 
and 3) compare the discriminating power of fasting blood 
glucose concentration with that of the homeostasis model 
assessment of insulin resistance (HOMA-IR) as MetS indi-
cators in African American children.
Methods
Study participants
Of the 128 participants enrolled in the summer of 2007, a 
full set of data was available for 108 African American chil-
dren who were part of the Taking Action Together Study, a 
community-based lifestyle modification program to reduce 
the risk for type 2 diabetes (described more fully elsewhere) 
(13; http://clinicaltrials.gov/ct2/show/NCT01039116). Study 
participants were recruited by distributing pamphlets at 
local recreational sites and schools in inner-city Oakland. 
Recruitment targeted African American children with a 
BMI at or above the 85th percentile. Exclusion criteria 
were being 8 years of age or younger, being 14 years of age 
or older, having fasting blood glucose ≥120 mg/dL, having 
any known metabolic disease, and taking medications 
known to affect the study outcomes. Parental informed 
consent was obtained from all subjects, and all protocols 
were approved by the institutional review boards at the 
University of California at Berkeley and the University of 
California at San Francisco. All participants were asked to 
report to the Children’s Hospital and Research Center in 
Oakland, California, after an overnight fast of at least 12 
hours for blood sample collection.
Anthropometric measurements
Body weight and height were measured to the nearest 0.1 
kg and 0.1 cm by using a digital electronic scale (BWB 800, 
Tanita, Japan) and a portable stadiometer, respectively. 
BMI, BMI percentiles, and BMI z scores were generated 
by using an age- and sex-specific calculator program (www.
cdc.gov/nccdphp/dnpa/growthcharts/resources/sas.htm). 
Researchers used a plastic, nonelastic measuring tape 
to measure waist circumference just above the iliac crest 
with the child in the standing position. Measurements 
were taken twice and, if a difference of more than 0.4 cm 
was found between measurements, a third measurement 
was taken and the mean calculated by using the closest 2 
values.
Biochemical measurements
Fasting blood samples were processed and analyzed by 
a commercial laboratory (LabCorp, Burlington, North 
Carolina) for concentrations of HDL-C and triglycerides 
by using the vertical auto profile cholesterol method (14). 
Pubertal development on a 5-point scale was assessed by 
using previously determined serum concentration cutoffs 
for luteinizing hormone and estradiol (15). Blood glucose 
was determined by using the hexokinase-peroxidase 
method (Glucose HK-60 radioimmunoassay, Diagnostic 
Chemicals, Oxford, Connecticut). Fasting insulin concen-
trations were determined by using enzyme immunoassay 
(Linco Research, Inc, St. Charles, Missouri). Fasting 
blood glucose and insulin values were used to calculate 
HOMA-IR, defined as fasting blood glucose (mmol/L) × 
insulin (μIU/mL)/22.5, and used as an index of insulin 
resistance (13).
Blood pressure measurements
Blood pressure was measured between 9 am and noon. 
Measurements were repeated until 2 consecutive systolic 
and diastolic measurements agreed within 4 and 2 mm 
Hg, respectively. Measurements were conducted twice 
at least 3 hours apart, and the second series of measure-
ments was used for analyses. Values were converted to z 
scores (matched for age, height, and sex) by using regres-
sion equations developed and reported elsewhere (16).
MetS incidence
Participants were defined as having MetS if they met 3 or 
more of the following criteria (4): triglycerides of at least 
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100 mg/dL, HDL-C less than or equal to 50 mg/dL, fasting 
blood glucose of at least 110 mg/dL (6.1 mmol/L), waist 
circumference above the 75th percentile, and systolic or 
diastolic blood pressure or both above the 90th percentile 
for age, sex, and height (10). Waist circumference values 
for the 75th-percentile cutoff, when matched for age and 
sex, were calculated by using regression equations devel-
oped specifically for African American children (17). In 
some analyses, the blood glucose component of MetS was 
replaced with values for HOMA-IR, by using a cutoff of 
2.5 as suggested previously for assessments of children 
(18). Throughout this article, the term MetSglucose is used 
to indicate cases using fasting blood glucose of at least 
110 mg/dL as 1 of the 5 components, MetSHOMA-IR is used 
to indicate cases using HOMA-IR above 2.5 as 1 of the 5 
components, and MetSglucose57 is used to indicate cases by 
using fasting blood glucose above the 57th percentile (87.7 
mg/dL) as 1 of the 5 components.
Statistical analyses
A complete set of data was available for 108 of the 125 par-
ticipants. These data were evaluated for skewedness and, 
if significant, Dixon’s test for outliers was used to identify 
unusual values. If unusual values were identified, all data 
for that participant were excluded from further analyses. 
Using Dixon’s test, we excluded data for 3 children, provid-
ing a final sample of 105 (45 boys and 60 girls). We ana-
lyzed differences in the characteristics of boys and girls, of 
overweight and obese groups, and of cases compared with 
noncases by using independent 2-tailed t tests following 
Levene’s test for equality of variances for continuous vari-
ables and the χ2 test for dichotomized variables. Because 
the term MetS is used to describe a single concept and 
has been defined as a condition comprising at least 3 of 5 
interrelated components, correlations among these compo-
nents, including tests for internal consistency (Cronbach 
α) were used to compare reliability of fasting blood glucose 
with HOMA-IR as 1 of the 5 MetS components.
Statistical procedures were performed using SPSS version 
16.0 (SPSS, Inc, Chicago, Illinois). Statistical significance 
was set at P < .05.
Results
Overall, 17% of this sample (9% of boys and 23% of girls) 
was classified as having MetSglucose because they had 
values that met the cutoff criteria defined previously by 
others for 3 or more components (Table 1). In comparison 
with overweight children (7% of boys and 14% of girls), 
obese children (10% of boys and 25% of girls) had less 
favorable values for key health indicators. A total of 9.5% 
of overweight children (7% of the boys and 14% of the girls) 
and 19% of obese children (10% of the boys and 24% of the 
girls) were classified as having MetSglucose.
Children who were classified as having MetSglucose had a 
significantly higher BMI percentile, waist circumference, 
triglycerides, insulin, systolic blood pressure, and HOMA-
IR, and lower HDL-C than those who were negative for 
MetSglucose (Table 2). Fasting blood glucose concentrations 
were not significantly different, however, for children with 
MetSglucose. Of the 105 children, only 1 had a fasting blood 
glucose value that exceeded the cut point of 110 mg/dL. 
Because this participant had values for 4 components that 
met the MetSglucose criteria, this blood glucose cutoff, when 
applied to this population of children, resulted in 100% 
true positives, 0 false positives, and 100% true negatives 
(Table 3). The corresponding HOMA-IR value was >11. 
Although specificity was 100%, sensitivity was 6%, indi-
cating that this component contributed little value for the 
purpose of diagnosing MetSglucose in this population.
Using HOMA-IR as 1 of the 5 components, we found a 38% 
prevalence of MetS in this sample of African American 
children. Replacing the fasting blood glucose component of 
MetS with HOMA-IR at the cutoff of 2.5 suggested previ-
ously for overweight and obese children (18) increased the 
number of cases from 18 for MetSglucose to 40 for MetSHOMA-
IR (Table 2). This HOMA-IR cutoff, when used to assess 
MetSHOMA-IR, resulted in more than 80% true positives and 
true negatives and less than 20% false positives and false 
negatives (Table 3). Specificity and sensitivity of HOMA-
IR as a MetS component were 83% and 88%, respectively. 
By using the MetSHOMA-IR cutoffs, we found that 14% of 
the overweight children (7% of boys and 29% of girls) and 
44% of obese children (29% of boys and 53% of girls) were 
classified as having MetSHOMA-IR.
The fasting blood glucose concentration cutoff of 110 mg/
dL was at the 99th percentile for this sample, whereas 
the HOMA-IR cutoff of 2.5 was at the 57th percentile. To 
more fairly compare the use of fasting blood glucose with 
HOMA-IR as components of MetS, MetSglucose57 was deter-
mined by using as the fifth component the 57th percentile 
for fasting blood glucose concentration in this sample, 
which was 87.7 mg/dL glucose. This fasting blood glucose 
concentration, when used to assess MetSglucose57 in this 
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population of children, resulted in more than 70% true 
positives and true negatives, and 28% false positives and 
18% false negatives (Table 3). Specificity of the 87.7 mg/dL 
glucose cutoff as a MetS component was calculated to be 
72% and sensitivity was 82%.
Fasting blood glucose concentration was not significantly 
related to any of the variables included in MetS except 
for diastolic blood pressure, whereas values for HOMA-IR 
were significantly related to all MetS variables except for 
diastolic blood pressure (Table 4a). Glucose concentration, 
when treated as a dichotomous variable and with cutoffs 
of either 110 mg/dL or 87.7 mg/dL, was not significantly 
related to any other dichotomized MetS components with 
the exception of triglycerides (Table 4b). By contrast, 
HOMA-IR treated as a dichotomous variable was signifi-
cantly related to dichotomized waist circumference, HDL-
C, and triglycerides.
The intercorrelations among the components were nota-
bly lower for the 5 MetSglucose (Cronbach α = 0.424) and 
MetSglucose57 components (0.425) than for the 5 MetSHOMA-
IR components (0.548). When other cutoff points for both 
glucose and HOMA-IR were evaluated, the highest α 
value observed was for a glucose concentration of 100 mg/
dL (0.428) and for HOMA-IR of 2.4 (0.553). Regardless of 
the glucose concentration cutoffs selected, α values were 
always lower with the glucose variable (≤0.428) than 
without it (0.429), indicating that including glucose did 
not contribute to the reliability of assessing MetS. By con-
trast, α values were higher with HOMA-IR cutoffs in the 
2 to 3 range (0.516-0.553) than without (0.429), indicating 
that HOMA-IR did contribute to the reliability of MetS 
assessment.
Discussion
The prevalence of MetS among children of different eth-
nicities and backgrounds has been reported in few stud-
ies, and the multiple definitions of MetS make it difficult 
to directly compare population prevalence. Researchers 
using data from a nationally representative sample of 
approximately 1,700 adolescents found MetS prevalence 
to be 13% among 12- to 19-year-old adolescent Mexican 
Americans, 11% among non-Hispanic whites, and 2.5% 
among non-Hispanic blacks (4). In our study, using the 
same MetS criteria, overall prevalence of MetSglucose was 
17% (9% of boys, 23% of girls) among a sample of 9- to 
13-year-old African American children recruited from 
inner-city Oakland, California. This finding was lower 
than the 31% prevalence reported for 12- to 19-year-old 
adolescents with a BMI in the 85th percentile or higher 
(4), a difference that may be attributable to the lower 
age of children in our sample. Our prevalence of 22% for 
girls was somewhat higher than the 18% prevalence for a 
sample of predominantly African American, mostly obese, 
adolescent girls aged 13 to 15 reported by others who used 
the same MetS criteria (11). The prevalence among girls in 
our sample was double the prevalence among boys, a find-
ing that is consistent with the sex differences we observed 
in body fatness (13). Using National Health and Nutrition 
Examination Survey (NHANES) III data for adolescents 
aged 12 to 19 — a sample that is more representative of 
the American civilian population — others have reported 
a higher overall prevalence among boys than girls (3,4). A 
follow-up study with a larger sample size will be needed 
to confirm the sex differences we observed for younger 
African American overweight and obese children.
The prevalence of MetSglucose was twice as high among 
obese as among overweight children in our sample (19% 
and 10%, respectively). In the obese group, 10% of boys 
and 25% of girls met the criteria for MetSglucose,whereas in 
the overweight group, 7% of boys and 14% of girls met the 
MetSglucose criteria. Our findings are consistent with analy-
ses of the NHANES III data set for young people aged 12 
to 19 years, in which the prevalence of MetS was reported 
to increase with BMI category (3,4). Thus, our results are 
similar to previous data yet provide additional information 
that describes the prevalence of MetS among overweight 
and obese African American children and suggest the need 
for additional assessments to further compare boys and 
girls.
Although fasting glucose concentration has been included 
by others as a MetS component, our results suggest that 
insulin resistance may be more reliably used to assess 
MetS in African American children. In our study, only 
1 participant had a fasting blood glucose concentration 
that exceeded the cut point of 110 mg/dL for MetS. Thus, 
although highly specific (100%), its use alone would have 
resulted in a large number (94%) of false negatives and 
very low sensitivity (6%). Other studies have suggested 
that, for African American children, insulin resistance 
is a strong predictor of type 2 diabetes (19), and insulin 
resistance has always been included previously as a MetS 
component (20). In our sample, fasting blood glucose and 
insulin concentrations were not significantly correlated. 
This is not surprising because hyperinsulinemia is known 
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to developmentally precede the hyperglycemic phase. 
Both fasting insulin concentrations and HOMA-IR have 
been shown to be highly correlated with more invasive, 
exacting, and labor-intensive measures of insulin sen-
sitivity in obese children and adolescents (21). Also, in 
our sample, fasting glucose concentrations, dichotomized 
for MetS assessment, were poorly correlated with the 
other 4 dichotomized components, whereas dichotomized 
HOMA-IR was significantly correlated. Finally, internal 
consistency among the MetS components was lower when 
MetSglucose was included than when MetSHOMA-IR was 
included. The high levels of specificity (83%) and sensitiv-
ity (88%) observed when using the HOMA-IR cutoff of 2.5 
as a MetS component suggests that, for African American 
children, insulin sensitivity should be used instead of 
glucose concentration to assess children for MetS. This 
conclusion is further supported by our comparison of 
HOMA-IR versus glucose when assessed at the same 
percentile for our sample (ie, the 57th percentile); efforts 
to identify a glucose concentration that outperformed 
HOMA-IR as a component were not successful.
Others have attempted to establish the best cutoff value 
for the HOMA-IR index as a predictor of MetS in children 
and adolescents. One group concluded that HOMA-IR 
values “close to 3” seem to be adequate (22), whereas a 
second group recommended that a cutoff for HOMA-IR of 
2.5 be used for obese prepubertal children (18). We chose 
to use a cutoff of 2.5 for our African American participants 
for comparison purposes, although Cronbach α was some-
what higher using HOMA-IR 2.4 than 2.5. Our results 
suggest the necessity of replacing the glucose component 
with HOMA-IR for MetS diagnosis in this population; the 
MetS prevalence of 38% in the current sample, determined 
using HOMA-IR in place of glucose as a component, sug-
gests that this population of children is seriously in need 
of intervention. A follow-up study is warranted to evaluate 
MetS prevalence in a larger and more diverse sample of 
African American children. The optimal HOMA-IR cutoff 
could also be confirmed in this larger sample.
Limitations of this study include restriction to low-income, 
inner-city African American children and exclusion of 
children with a BMI less than the 85th percentile when 
matched for age and sex. These limitations preclude 
comparisons among children of different races, ages, and 
socioeconomic backgrounds, and comparisons with lower 
BMI children. This is a cross-sectional analysis of data, 
precluding a cause-and-effect relationship. 
In conclusion, among African American boys and girls 
living in inner-city Oakland, we found that MetS preva-
lence was 2 to 3 times higher for girls than for boys, 
even when separated according to the CDC-defined BMI 
categories, and was twice as high using HOMA-IR (38%) 
in place of glucose (17%) as a MetS component. Our data 
suggest that insulin resistance should be used as a MetS 
component in place of fasting blood glucose, because insu-
lin resistance was more highly correlated with other MetS 
components, provided fewer false negatives and false posi-
tives, and was more sensitive for identifying MetS in this 
high-risk pediatric population.
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Tables
Table 1. Anthropometric and Hematologic Characteristics of Participants and Differences by Sex and Body Weight, Taking Action 
Together Study, Oakland, California, 2007 
Demographic Characteristics
Sex Body Weight
Boys, 
Mean (SE) 
n = 45
Girls, 
Mean (SE) n = 60 P Valuea
Overweight,b 
Mean (SE) n = 21
Obese,b 
Mean (SE) n = 84 P Valuea
Age, y (SD) 10.6 (1.03) 10.6 (1.18) .81 10.3 (1.01) 10. (1.13) .16
Pubertal stage (-point scale) 2.11 (1.8) 3. (1.21) <.001 2. (1.66) 2.9 (1.) .30
Height, cm 18 (8.93) 11 (9.2) .06 16 (8.00) 10 (9.36) .0
Weight, kg 9.3 (18.) 69.0 (18.8) .01 . (.32) 69.6 (18.2) <.001
BMI percentile 96.0 (.3) 9.8 (2.0) .02 91.0 (3.6) 98. (1.2) <.001
BMI, z score 1.96 (0.0) 2.21 (0.3) .00 1.3 (0.21) 2.29 (0.32) <.001
WC, cm 8. (1.8) 93.0 (1.9) .00 1. (.11) 93.9 (13.) <.001
WC >th percentilec % of sample 96 9 .90 6 100 <.001d
HDL-C, mg/dL . (13.2) 2. (11.) .0 63.0 (1.) 2. (10.9) <.001
Triglycerides, mg/dL 63. (2.1) 6.3 (2.2) .01 60.0 (23.) 3. (26.8) .0
Fasting glucose, mg/dL 8.6 (.9) 88.3 (1.3) .6 8. (6.1) 88.1 (13.2) .82
Insulin, μIU/mL 8.9 (.08) 16.3 (12.3) <.001 6.8 (.02) 1. (11.2) <.001
HOMA-IRe 1.86 (1.1) 3. (2.68) <.001 1.9 (0.93) 3.1 (2.) <.001
sBP, mm/Hg 106 (8.9) 10 (.38) . 102 (6.26) 106 (8.22) .06
dBP, mm/Hg 62. (8.0) 62. (.83) .99 9.6 (.90) 63.2 (8.3) .0
sBP, z score 0.02 (0.) −0.06 (0.72) .8 −0.22 (0.56) 0.02 (0.) .1
dBP, z score 0.01 (0.69) −0.03 (0.72) .81 −0.22 (0.50) 0.0 (0.) .1
Metabolic syndrome,f n (% of sample) 
with glucose ≥110 mg/dL
 (8.9) 1 (23.3) .0d 2 (9.) 16 (19.0)f .30d
 
Abbreviations: SE, standard error; SD, standard deviation; BMI, body mass index; WC, waist circumference; HDL-C, high-density lipoprotein cholesterol; HOMA-
IR, homeostasis model assessment of insulin resistance; sBP, systolic blood pressure; dBP, diastolic blood pressure. 
a Differences determined using 2-tailed t test following Levene’s test for equality of variances (with exception noted in footnote c). 
b Overweight is defined as BMI >85 to <95th percentile; obese is defined as BMI ≥95th percentile matched for age and sex. 
c Waist circumference percentiles calculated by using regression equations developed by Fernandez et al (1) for African American children with adjustments 
for age and sex. 
d Difference determined by using χ2 test. 
e HOMA-IR, defined as fasting blood glucose (mmol/L) × insulin (μIU/mL)/22.5, and used as an index of insulin resistance. Cutoffs for defining metabolic syn-
drome in children taken from de Ferranti et al (). 
f Of those children with BMIs ≥95th percentile, the proportion of girls (29%) compared with boys (18%) that met the criteria for having metabolic syndrome was 
not significantly different (χ2 test).
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Table 2. Anthropometric and Hematologic Characteristics of Participants With and Without Metabolic Syndrome Using 2 Sets of 
Criteria,a Taking Action Together Study, Oakland, California, 2007 
Participant Characteristics
MetSglucose Status MetSHOMA-IR Status
Negative, 
Mean (SEM) n 
= 87
Positive, 
Mean (SEM) n 
= 18 P Valueb
Negative, 
Mean (SEM) n 
= 65
Positive, 
Mean (SEM) n 
= 40 P Valueb
Sex (0 = girls; 1 = boys) 0. (0.0) 0.22 (0.3) .0 0. (0.0) 0.2 (0.) .00
Pubertal stage (-point scale) 2.80 (1.) 3.22 (1.) .28 2.66 (1.) 3.22 (1.9) .06
BMI, z score 2.0 (0.9) 2.29 (0.3) .0 1.9 (0.9) 2.31 (0.3) <.001
Waist circumference, cm 8.9 (1.) 96.3 (13.1) .03 8.2 (1.3) 96.1 (1.8) <.001
HDL-C, mg/dL 6. (12.) . (.18) <.001 60. (11.6) .9 (.6) <.001
Triglycerides, mg/dL 62.8 (20.) 109.0 (19.1) <.001 60.1 (19.6) 88.1 (2.8) <.001
Fasting glucose, mg/dL 86.6 (.8) 9.9 (26.0) .12 86.2 (.8) 90.9 (18.1) .06
Fasting insulin, μIU/mL 12.0 (10.) 1. (10.) .0 9.83 (10.3) 18.1 (9.0) <.001
HOMA-IR 2.61 (2.21) .08 (2.1) .01 2.09 (2.13) .0 (2.12) <.001
sBP, z score −0.10 (0.69) 0.31 (0.80) .03 −0.18 (0.65) 0.22 (0.) .00
dBP, z score −0.05 (0.67) 0.18 (0.86) .20 −0.08 (0.65) 0.09 (0.8) .2
 
Abbreviations: BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; sBPz, systolic 
blood pressure z score; dBPz, diastolic blood pressure z score. 
a Defined as a glucose concentration cutoff of ≥110mg/dL (MetSglucose) or a HOMA-IR cutoff of ≥2.5 (MetSHOMA-IR). 
b Differences determined by using 2-tailed t tests following Levene’s test for equality of variances with the exception that χ2 test was used for the dichotomous 
variable “sex.”
Table 3. Reliability of Glucose Compared With HOMA-IR as 1 of the 5 Components of Metabolic Syndrome, Taking Action Together 
Study, Oakland, California, 2007 
Cutoffs
Positives Negatives
Specificity,f 
%
Sensitivity,g 
%
No. of 
Casesa
True,b 
n (%)
False,c 
n (%)
No. of Cases,a 
n
True,d 
n (%)
False,e 
n (%)
Glucose ≥110 mg/dLh 18 1 (100) 0 8 8 (100) 1 (9) 100 6
HOMA-IR ≥2.5i 0 3 (88) 11 (1) 6  (83)  (13) 83 88
Glucose ≥87.7 mg/dLi 33 2 (82) 20 (28) 2 2 (2) 6 (18) 2 82
 
Abbreviations: HOMA-IR, homeostasis model assessment of insulin resistance; HDL-C, high-density lipoprotein cholesterol; MetS, metabolic syndrome. 
a For all conditions,  components were evaluated: waist circumference, HDL-C, triglycerides, and blood pressure. A fifth component (glucose concentration or 
HOMA-IR value) was evaluated at the values indicated in the cutoffs column.  
b True positives, % = [(number of positive cases for which glucose or HOMA-IR values exceeded the indicated cutoff) / (total number of positive cases)] × 100. 
c False positives, % = [(number of negative cases for which glucose or HOMA-IR values exceeded the indicated cutoff) / (total number of negative cases)] × 
100. 
d True negatives, % = [(number of negative cases for which glucose or HOMA-IR values did not exceed the indicated cutoff) / (total number of negative cases)] 
× 100. 
e False negatives, % = [(number of positive cases for which glucose or HOMA-IR values did not exceed the indicated cutoff) / (total number of positive cases)] × 
100. 
f Specificity = [(number of true negatives) / (number of true negatives + number of false positives)] × 100. 
g Sensitivity = [(number of true positives) / (number of true positives + number of false negatives)] × 100. 
h Glucose concentration cutoff for MetS as recommended by de Ferranti et al (). 
i HOMA-IR, defined as fasting blood glucose (mmol/L) × insulin (μIU/mL)/22.5. HOMA-IR cutoff for MetS as recommended by Madeira et al (18). In this sample, 
% of participants had HOMA-IR <2. and % had fasting blood glucose concentrations <8. mg/dL.
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Table 4. Pearson’s Correlations and Significance Between Values for Blood Glucose or Insulin Resistance and Other Metabolic Risk 
Factors (n = 105), Taking Action Together Study, Oakland, California, 2007 
Table 4a. Correlations, treating each component as a continuous variable.
MetS Component
Glucose, mg/dL HOMA-IR
r P Value r P Value
Waist circumference, cm 0.13 .19 0.1 <.001
HDL-C, mg/dL −0.10 .33 −0.27 .006
Triglycerides, mg/dL 0.19 .06 0.26 .00
sBP, z score −0.40 .69 0.21 .03
dBP, z score −0.20 .0 0.1 .1
Insulin, μIU/mL 0.06 . 0.98 <.001
Table 4b. Correlations, treating each component as a dichotomous variable.
MetS Component 
Glucose  
≥110 mg/dLa
Glucose,  57th Percentile or  
≥87.7 mg/dLb
HOMA-IR,  
57th Percentile or ≥2.5b
r P Value r P Value r P Value
Waist circumference, cmc 0.02 .82 0.02 .83 0.20 .0
HDL-Cd 0.10 .29 0.08 .2 0.3 <.001
Triglyceridese 0.21 .03 0.1 .08 0.28 .003
BPf −0.03 .6 0.13 .1 0.0 .6
 
Abbreviations: MetS, metabolic syndrome; HOMA-IR, homeostasis model assessment of insulin resistance; HDL-C, high-density lipoprotein cholesterol;  sBP; 
systolic blood pressure; dBP, diastolic blood pressure; BP, blood pressure. 
a Glucose concentration cutoff at ≥110 mg/dL: 0 = below cutoff; 1 = above cutoff. 
b HOMA-IR cutoff of ≥2.5 was at the 57th percentile for this population (0 = below cutoff, 1 = above cutoff). The corresponding 57th percentile glucose concen-
tration in this population was 88 mg/dL. 
c Waist circumference cutoff for MetS was >th percentile when matched for age, sex and race: 0 = below cutoff; 1 = above cutoff. 
d HDL-C cutoff for MetS was <0 mg/dL: 0 = above cutoff; 1 = below cutoff. 
e Triglycerides cutoff for MetS was ≥100 mg/dL: 0 = below cutoff; 1 = above cutoff. 
f BP cutoff for MetS: sBP and/or dBP >90th percentile when matched for age, sex, and height: 0 = below cutoff; 1 = above cutoff.
